Positive feedback loop between vision-related anxiety and self-reported visual difficulty

Carregando...
Imagem de Miniatura
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS INC
Autores
POPOVA, Lilia T.
ABUZAITOUN, Rebhi O.
FRESCO, David M.
ANDREWS, Chris A.
MUSCH, David C.
EHRLICH, Joshua R.
JAYASUNDERA, K. Thiran
Citação
OPHTHALMIC GENETICS, v.44, n.4, p.327-333, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BackgroundPatients with Inherited Retinal Diseases typically experience progressive, irreversible vision loss resulting in low vision and blindness. As a result, these patients are at high risk for vision-related disability and psychological distress, including depression and anxiety. Historically, the relationship between self-reported visual difficulty (encompassing metrics of vision-related disability and quality of life, among others) and vision-related anxiety has been regarded as an association and not a causal relationship. As a result, there are limited interventions available that address vision-related anxiety and the psychological and behavioral components of self-reported visual difficulty.Materials and MethodsWe applied the Bradford Hill criteria to evaluate the case for a bidirectional causal relationship between vision-related anxiety and self-reported visual difficulty.ResultsThere is sufficient evidence to satisfy all nine of the Bradford Hill criteria of causality (strength of association, consistency, biological gradient, temporality, experimental evidence, analogy, specificity, plausibility, and coherence) for the relationship between vision-related anxiety and self-reported visual difficulty.ConclusionsThe evidence suggests that there is a direct positive feedback loop-a bidirectional causal relationship-between vision-related anxiety and self-reported visual difficulty. More longitudinal research on the relationship between objectively-measured vision impairment, self-reported visual difficulty, and vision-related psychological distress is needed. Additionally, more investigation of potential interventions for vision-related anxiety and visual difficulty is needed.
Palavras-chave
Anxiety, disability, quality of life, low vision
Referências
  1. Akuffo KO, 2021, BMC PSYCHOL, V9, DOI 10.1186/s40359-021-00558-x
  2. Assi L, 2021, JAMA OPHTHALMOL, V139, P526, DOI 10.1001/jamaophthalmol.2021.0146
  3. Bitar MS, 2019, CORNEA, V38, P684, DOI 10.1097/ICO.0000000000001932
  4. Blanco C, 2014, DEPRESS ANXIETY, V31, P756, DOI 10.1002/da.22247
  5. Brenes GA, 2005, J AM GERIATR SOC, V53, P34, DOI 10.1111/j.1532-5415.2005.53007.x
  6. Caballe-Fontanet D, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19020820
  7. Carriere I, 2013, J AFFECT DISORDERS, V151, P164, DOI 10.1016/j.jad.2013.05.071
  8. Choi S, 2018, JAMA OPHTHALMOL, V136, P1432
  9. Choi S, 2018, JAMA OPHTHALMOL, V136, P1399, DOI 10.1001/jamaophthalmol.2018.3892
  10. Clancy F, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhurn.2016.00534
  11. Cosh S, 2018, INT J GERIATR PSYCH, V33, P598, DOI 10.1002/gps.4827
  12. D'Amanda CS, 2020, SURV OPHTHALMOL, V65, P562, DOI 10.1016/j.survophthal.2020.02.002
  13. DiMatteo MR, 2000, ARCH INTERN MED, V160, P2101, DOI 10.1001/archinte.160.14.2101
  14. Diniz A, 2016, OPHTHALMOLOGY, V123, P754, DOI 10.1016/j.ophtha.2015.12.014
  15. Fedak KM, 2015, EMERG THEMES EPIDEMI, V12, DOI 10.1186/s12982-015-0037-4
  16. Frank CR, 2019, JAMA OPHTHALMOL, V137, P793, DOI 10.1001/jamaophthalmol.2019.1085
  17. Garip G, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1169-z
  18. Genovese G, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57060628
  19. Georgiou M, 2021, CLIN EXP OPHTHALMOL, V49, P270, DOI 10.1111/ceo.13917
  20. Goldstein JE, 2014, JAMA OPHTHALMOL, V132, P1169, DOI 10.1001/jamaophthalmol.2014.1747
  21. Goldstein JE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1028, DOI 10.1001/archophthalmol.2012.1197
  22. Guidi J, 2020, PSYCHOTHER PSYCHOSOM, V90, P11, DOI 10.1159/000510696
  23. Guo Xinxing, 2023, JAMA Netw Open, V6, pe2254006, DOI 10.1001/jamanetworkopen.2022.54006
  24. Heesterbeek TJ, 2017, OPHTHAL PHYSL OPT, V37, P385, DOI 10.1111/opo.12388
  25. Hendriks SM, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0946-y
  26. HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503
  27. Horowitz A, 2005, AGING MENT HEALTH, V9, P563, DOI 10.1080/13607860500193500
  28. Horowitz A, 2006, J GERONTOL B-PSYCHOL, V61, pS274, DOI 10.1093/geronb/61.5.S274
  29. Hyon J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40539-0
  30. Jack K, 2010, MANUAL THER, V15, P220, DOI 10.1016/j.math.2009.12.004
  31. Jackson JS, 2010, AM J PUBLIC HEALTH, V100, P933, DOI 10.2105/AJPH.2008.143446
  32. Kempen GIJM, 2014, AM J GERIAT PSYCHIAT, V22, P309, DOI 10.1016/j.jagp.2012.08.007
  33. Kempen GIJM, 2012, QUAL LIFE RES, V21, P1405, DOI 10.1007/s11136-011-0061-y
  34. Kong XM, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004632
  35. Lacy GD, 2020, OPHTHALMIC GENET, V41, P315, DOI 10.1080/13816810.2020.1776337
  36. Lam BL, 2008, ARCH OPHTHALMOL-CHIC, V126, P975, DOI 10.1001/archopht.126.7.975
  37. Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
  38. Lim MC, 2013, J GLAUCOMA, V22, P439, DOI 10.1097/IJG.0b013e31824cd0ae
  39. Lundeen EA, 2022, OPHTHAL EPIDEMIOL, V29, P171, DOI 10.1080/09286586.2021.1918177
  40. Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
  41. Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
  42. McEwen Bruce S, 2017, Chronic Stress (Thousand Oaks), V1, DOI 10.1177/2470547017692328
  43. McEwen BS, 2011, ANNU REV MED, V62, P431, DOI 10.1146/annurev-med-052209-100430
  44. McGrady A, 2009, J CARDIOPULM REHABIL, V29, P358, DOI 10.1097/HCR.0b013e3181be7a8f
  45. Mennin DS, 2013, CLIN PSYCHOL-SCI PR, V20, P258, DOI 10.1111/cpsp.12038
  46. Nollett C, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026163
  47. Nuzbrokh Y, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-4726
  48. Office of Disease Prevention and Health Promotion Office of the Assistant Secretary for Health, INCR US VIS REH SERV
  49. Ottaviani C, 2016, PSYCHOL BULL, V142, P231, DOI 10.1037/bul0000036
  50. Owsley C, 2019, JAMA OPHTHALMOL, V137, P801, DOI 10.1001/jamaophthalmol.2019.1084
  51. Owsley C, 2009, ARCH OPHTHALMOL-CHIC, V127, P681, DOI 10.1001/archophthalmol.2009.55
  52. Popova LT, 2023, OPHTHALMIC GENET, V44, P11, DOI 10.1080/13816810.2022.2144901
  53. Rees G, 2010, INVEST OPHTH VIS SCI, V51, P2891, DOI 10.1167/iovs.09-5080
  54. Robinson ME, 2004, PAIN MED, V5, P66, DOI 10.1111/j.1526-4637.2004.04002.x
  55. Sahel JA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017111
  56. Salman M, 2020, AM J OPHTHALMOL, V216, P207, DOI 10.1016/j.ajo.2020.02.009
  57. Sekimitsu Sayuri, 2022, Can J Ophthalmol, DOI 10.1016/j.jcjo.2022.11.019
  58. Senra H, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-06252-1
  59. Shah K, 2020, EYE, V34, P290, DOI 10.1038/s41433-019-0712-8
  60. SHMUELYDULITZKI Y, 1995, AM J GERIAT PSYCHIAT, V3, P325, DOI 10.1097/00019442-199503040-00007
  61. Sims M, 2016, J EPIDEMIOL COMMUN H, V70, P187, DOI 10.1136/jech-2015-206390
  62. Stringham J, 2018, EYE CONTACT LENS, V44, P50, DOI 10.1097/ICL.0000000000000301
  63. Swamy BN, 2009, ACTA OPHTHALMOL, V87, P335, DOI 10.1111/j.1755-3768.2008.01203.x
  64. Tseng YC, 2018, QUAL LIFE RES, V27, P1957, DOI 10.1007/s11136-018-1799-2
  65. Ustun B, 2009, WORLD PSYCHIATRY, V8, P82
  66. Ulhaq ZS, 2022, THER ADV OPHTHALMOL, V14, DOI 10.1177/25158414221090100
  67. van der Aa HPA, 2016, OPHTHAL PHYSL OPT, V36, P584, DOI 10.1111/opo.12313
  68. van der Aa HPA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6127
  69. van der Aa HPA, 2015, INVEST OPHTH VIS SCI, V56, P849, DOI 10.1167/iovs.14-15848
  70. van der Aa HP., 2016, BMJ-BRIT MED J, V353, pi1995
  71. van Nispen RMA, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006543.pub2
  72. Wang MR, 2021, EXP EYE RES, V213, DOI 10.1016/j.exer.2021.108853
  73. Wu N, 2022, BMJ OPEN, V12, DOI 10.1136/bmjopen-2020-046194